ClinicalTrials.gg
Not yet recruitingNCT07515560Updated Apr 7, 2026

Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study

An observational study in Dyslipidemia, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD. — 1 open to participants now, 4 under way, none of them phase 3. Dyslipidemias · Daewoong Pharmaceutical Co. LTD..

Started
2026
the only one that year
Observational
7 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD., this one is the only one that started in 2026, is one of 7 observational ones, and was the 12th registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD. is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD., or all of them as a file.
02

Study summary

This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg in Korean patients with dyslipidemia in real-world clinical practice.

Patients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.

Read the detailed description

This study is a prospective, non-interventional, multi-center observational study conducted in Korea to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg (Pitavastatin calcium/Ezetimibe) in patients with dyslipidemia in routine clinical practice.

Eligible patients aged 19 years or older who require treatment with Baroezet Tablet will be enrolled after providing written informed consent. Treatment decisions, including dosage and duration, will be made at the discretion of the treating physician in accordance with approved labeling.

Data will be collected at baseline, approximately 12 weeks, and 24 weeks, based on routine clinical visits. The primary efficacy endpoint is the percent change in LDL-C from baseline to 24 weeks. Secondary endpoints include changes in lipid parameters (TC, TG, HDL-C, non-HDL-C), HbA1c, and achievement of LDL-C targets according to risk categories.

Safety will be assessed by monitoring adverse events and laboratory abnormalities, including liver enzymes and creatine kinase levels.

Approximately 15,000 patients will be enrolled across multiple centers in Korea.

03

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • Dyslipidemia
  • LDL-C
  • Statin
  • Ezetimibe
  • Observational Study
  • Real-world
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study will enroll adult patients aged 19 years or older who are diagnosed with dyslipidemia in routine clinical practice in Korea. Eligible patients are those who require treatment with Baroezet Tablet 1/10 mg based on the physician's clinical judgment and provide written informed consent.

Patients will be recruited from multiple centers across Korea in a real-world setting. Treatment decisions, including initiation and continuation of Baroezet Tablet, will be made according to routine clinical practice. Patients with contraindications to the study drug, including hypersensitivity to its components, active liver disease, or pregnancy, will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥19 years
  • Patients diagnosed with dyslipidemia
  • Patients who require treatment with Baroezet Tablet
  • Patients who provide written

Exclusion criteria

Exclusion Criteria:

  • to study drug components
  • Active liver disease
  • Pregnant or breastfeeding women
  • Patients considered inappropriate by investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Baroezet Treatment Group

    Patients with dyslipidemia who are prescribed Baroezet Tablet 1/10 mg according to routine clinical practice will be observed for approximately 24 weeks.

06

What researchers measure

Primary outcomes

  1. Percent Change in LDL-C from Baseline to Week 24

    Percent change in LDL-C levels from baseline to approximately 24 weeks after treatment initiation.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Percent Change in LDL-C at Week 12

    Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to approximately 12 weeks after treatment initiation.

    Time frame: Baseline to Week 12

  2. Percent Change in Total Cholesterol (TC)

    Percent change in total cholesterol (TC) from baseline to approximately 12 weeks after treatment initiation.

    Time frame: Baseline to Week 12

  3. Percent Change in Triglycerides (TG)

    Percent change in triglyceride (TG) levels from baseline to approximately 12 weeks.

    Time frame: Baseline to Week 12

  4. Percent Change in Total Cholesterol (TC)

    Percent change in total cholesterol (TC) from baseline to approximately 24 weeks after treatment initiation.

    Time frame: Baseline to Week 24

  5. Percent Change in Triglycerides (TG)

    Percent change in triglyceride (TG) levels from baseline to approximately 24 weeks.

    Time frame: Baseline to Week 24

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Mar 2027, 10 months later.

Of 34 industry-sponsored observational studies under Dyslipidemias, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's planned 10 months is below that.

Counting every sponsor, half of 90 studies reached it within 40 months; a quarter within 23 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07515560
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Yun Jeong Kong
Contact
yjkong246@daewoong.co.kr
82-10-3206-5162

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion